Enwei Pharmaceutical Résultats passés
Passé contrôle des critères 0/6
Enwei Pharmaceutical's earnings have been declining at an average annual rate of -12%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5.5% per year. Enwei Pharmaceutical's return on equity is 3.5%, and it has net margins of 4.6%.
Informations clés
-12.0%
Taux de croissance des bénéfices
-20.5%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 5.5% |
| Rendement des fonds propres | 3.5% |
| Marge nette | 4.6% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Enwei Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 776 | 35 | 339 | 8 |
| 30 Jun 24 | 778 | 40 | 334 | 12 |
| 31 Mar 24 | 778 | 68 | 306 | 16 |
| 31 Dec 23 | 785 | 86 | 293 | 17 |
| 30 Sep 23 | 778 | 91 | 284 | 18 |
| 30 Jun 23 | 752 | 93 | 268 | 14 |
| 31 Mar 23 | 735 | 75 | 276 | 9 |
| 01 Jan 23 | 692 | 68 | 260 | 8 |
| 30 Sep 22 | 676 | 86 | 253 | 6 |
| 01 Jan 22 | 680 | 102 | 265 | 4 |
| 30 Sep 21 | 675 | 103 | 240 | 4 |
| 31 Dec 20 | 634 | 99 | 243 | 5 |
| 31 Dec 19 | 621 | 83 | 294 | 4 |
| 31 Dec 18 | 593 | 86 | 291 | 4 |
| 31 Dec 17 | 559 | 64 | 272 | 4 |
Des revenus de qualité: 301331 has a large one-off gain of CN¥9.4M impacting its last 12 months of financial results to 30th September, 2024.
Augmentation de la marge bénéficiaire: 301331's current net profit margins (4.6%) are lower than last year (11.7%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 301331's earnings have declined by 12% per year over the past 5 years.
Accélération de la croissance: 301331's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 301331 had negative earnings growth (-61.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement des fonds propres
ROE élevé: 301331's Return on Equity (3.5%) is considered low.